Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GT101 in Metastatic/Recurrent Advanced Solid Tumors
NCT06077903Phase 1Terminated
- Sponsor
- Grit Biotechnology
- Start
- Jul 2021
- Primary completion
- Dec 2025
- Modality
- Allogeneic CAR-T, Tumor-Infiltrating Lymphocytes (TILs), TCR-Engineered T Cells
01
Overview
Phase 1, open-label, single-arm trial of autologous tumor infiltrating lymphocytes GT101 in solid tumor, sponsored by Grit Biotechnology. Primary endpoint: Incidence and severity of adverse events at 3 years. Started Jul 2021; status: terminated.
02
Drugs
autologous tumor infiltrating lymphocytes GT101
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT06077903.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06077903.